Palatin Forum: Community User: allesaufaurora

Hat nicht lange gehalten

As of September 30, 2024, Palatin's cash and cash equivalents were $2.4 million. Palatin did receive a scheduled $2.5 million deferred payment in November 2024 from Cosette Pharmaceuticals related to the sale of Vyleesi. Obviously, since this was received in November, it is not included in our September 30 cash and cash equivalents balance. Future investment and activities will be focused and limited to our core programs in obesity. We've retained an investment bank to conduct, explore and evaluate strategic options for our non-obesity programs. At this stage, there is significant interest in and ongoing discussions for our Phase III dry eye disease program, our early-stage glaucoma and retina development programs and our Phase II ulcerative colitis program from multiple parties.

We believe the pharmacological treatment of obesity is in the early stages of a multiyear cycle of innovation and will have a market value greater than $100 billion per year. We do have large companies that are very interested in the dry eye disease programs and then we have -- as well as the glaucoma and retinal. So it may be a mixture. You may see a out-licensing of dry eye disease and then a corporate -- and a corporate combination of assets for the others that are a little bit earlier. Our expectation, not Nostradamus-confirmed, is that we're going to have multiple deals as we go forward. And some of them could be absolutely as early as the first quarter of next year.

Nächster Anlauf... 🤞🏻

Gibt's eine Erklärung?

Glückwunsch, "länger" = +300%? 🤑

Grüße dich cabal, ich schau mal vorbei, war länger bei Vidac drin. Jetzt bin ich auf der Suche

https://www.gurufocus.com/news/2539968/palatin-technologies-inc-ptn-q4-2024-earnings-call-transcript-highlights-strategic-moves-and-financial-performance

Hmm, Nachkauf bei 0,63€ war wohl nicht der schlechteste. 😁

"Palatin’s net loss for the quarter and fiscal year ended June 30, 2024, was $8.6 million and $29.7 million, or $(0.51) and $(2.02) per basic and diluted common share, respectively, compared to a net loss of $9.8 million and $24.0 million, or $(0.84) and $(2.21) per basic and diluted common share, respectively, for the same periods in 2023. The decrease in net loss for the quarter ended June 30, 2024, over the quarter ended June 30, 2023, was mainly due to the decrease in Vyleesi operating expenses, offset by the elimination of net product revenue of Vyleesi and the recognition of the change in fair value of warrant liabilities for the quarter ended June 30, 2023. The increase in net loss for the fiscal year ended June 30, 2024, over the prior fiscal year, was mainly due to the recognition of an income tax benefit related to the sale of New Jersey Net Operating Losses, and the recognition of a gain on purchase commitments for the fiscal year ended June 30, 2023."

https://palatin.com/press_releases/palatin-reports-fourth-quarter-and-fiscal-year-ended-2024-financial-results-provides-update-on-clinical-programs-strategic-priorities-and-anticipated-milestones/

traderfox aktien-terminalhttps://aktie.traderfox.comaktien-terminal: das aktien ... - traderfox https://www.google.com/url?q=https://aktie.traderfox.com/&sa=u&ved=2ahukewj78nk6-oaiaxvd_7sihdfii2iqfnoecbqqaq&usg=aovvaw3gsrascafd_arfszo8kwbp Das ist der Aktienterminal von trader fox Da kannst du die wkn eingeben und Aktien super abchecken 👍👍👍

Bilanz-Analyse 2023 Cash-Quote 99 % 0 %25 %50 %75 %100 % 1,00 % aller Aktien sind besser bewertet.  Ranking Eigenkapitalquote 14 % 0 %25 %50 %75 %100 % 85,38 % aller Aktien sind besser bewertet.  Ranking

"Palatin’s net loss was $8.4 million, or $(0.53) per common share, compared to a net loss of $8.7 million, or $(0.76) per common share for the comparable period last year. The decrease over the comparable quarter last year was mainly due to a larger operating loss in fiscal 2024 offset by the higher other income primarily from changes in the fair value of warrant liabilities."